1. Home
  2. GH

GH

Guardant Health Inc.

Logo Guardant Health Inc.

Health Care

Medical Specialities

Nasdaq

as 04-18-2024 3:28pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Founded: N/A Country:
United States
United States
Employees: N/A City: PALO ALTO
Market Cap: 2.0B IPO Year: 2018
Target Price: $40.44 AVG Volume (30 days): 2.0M
Analyst Decision: Buy Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.28 EPS Growth: N/A
52 Week Low/High: $16.92 - $41.06 Next Earning Date: 05-07-2024
Revenue: $563,948,000 Revenue Growth: 25.45%
Revenue Growth (this year): 21.28% Revenue Growth (next year): 21.69%

Share on Social Networks: